BLUE Stock Recent News

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) o.

Chibougamau, Quebec--(Newsfile Corp. - May 9, 2025) - Mines D'Or Orbec/Orbec Gold Mines (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the company is participating in the upcoming 121 Mining Investment Conference in London. John Tait, CEO of Mines D'Or Orbec/Orbec Gold Mines will be presenting about the Company's recent and future planned activities.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025. Stockholders that hold shares of bluebird common stock through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the “Board”) reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and.

Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.

Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the “Merger Agreement”.

Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago.

NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).